Literature DB >> 23599038

Nonsteroidal anti-inflammatory drugs reduce the production of quorum sensing regulated virulence factors and swarm in motility in human pathogen Pseudomonas aeruginosa [corrected].

S Ulusoy1, G Bosgelmez-Tinaz.   

Abstract

Antibiotics are commonly used for the treatment of microbial infections. With the widespread appearance of multi antibiotic-resistant bacteria, it is becoming increasingly more difficult to treat bacterial infections with conventional antibiotics. Thus, there is an increasing need for new strategies to cope with infectious diseases. The discovery that many pathogenic bacteria employ quorum sensing (QS) to regulate their pathogenicity and virulence factor production makes the QS system an attractive target for antimicrobial therapy. It has been suggested that inactivating the QS system of a pathogen can result in a significant decrease in virulence factor production. In this study, a variety of NSAIDs, such as diclofenac, ibufen, ketoprofen, naproxen, piroxicam were screened for their capacity to reduce the production of QS-regulated virulence factors and swarming motility in the human pathogen P. aeruginosa. Ketoprofen, diclofenac, ibufen, naproxen and piroxicam reduced the elastase production by 28-47% compared to the untreated cultures. Pyocyanin production was also inhibited by these compounds but to a lesser extent. In swarming assay plates, ketoprofen and diclofenac treated PA01 strain displayed significant reductions in swarming motility (81% and 84% respectively). These findings suggest that especially, ketoprofen and diclofenac, may prevent bacterial colonization, and thereby reducing biofilm formation, by interfering with QS-controlled swarming motility of P. aeruginosa and combinatory chemotherapy with both conventional antibiotics and tested NSAIDs could be used for the treatment of chronic infections caused by P. aeruginosa and other clinically important pathogens which regulate their pathogenicity via QS. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23599038     DOI: 10.1055/s-0033-1343430

Source DB:  PubMed          Journal:  Drug Res (Stuttg)        ISSN: 2194-9379


  7 in total

1.  Identification of the Hypertension Drug Guanfacine as an Antivirulence Agent in Pseudomonas aeruginosa.

Authors:  Bethany K Okada; Anran Li; Mohammad R Seyedsayamdost
Journal:  Chembiochem       Date:  2019-07-03       Impact factor: 3.164

2.  Comparison of anti-bacterial efficiency of ibuprofen, diclofenac, and calcium hydroxide against Enterococcus faecalis in an endodontic model: An in vitro study.

Authors:  Sherin Jose Chockattu; B S Deepak; K Mallikarjun Goud
Journal:  J Conserv Dent       Date:  2018 Jan-Feb

3.  Antimicrobial Activity of Ibuprofen against Cystic Fibrosis-Associated Gram-Negative Pathogens.

Authors:  Parth N Shah; Kimberly R Marshall-Batty; Justin A Smolen; Jasur A Tagaev; Qingquan Chen; Christopher A Rodesney; Henry H Le; Vernita D Gordon; David E Greenberg; Carolyn L Cannon
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

4.  Meloxicam inhibits biofilm formation and enhances antimicrobial agents efficacy by Pseudomonas aeruginosa.

Authors:  Pengfei She; Yangxia Wang; Zhen Luo; Lihua Chen; Ruichen Tan; Yanle Wang; Yong Wu
Journal:  Microbiologyopen       Date:  2017-11-27       Impact factor: 3.139

Review 5.  Inhibitors of Bacterial Swarming Behavior.

Authors:  Sina Rütschlin; Thomas Böttcher
Journal:  Chemistry       Date:  2019-10-24       Impact factor: 5.236

6.  Drugs with new lease of life as quorum sensing inhibitors: for combating MDR Acinetobacter baumannii infections.

Authors:  Noura M Seleem; Hemat K Abd El Latif; Moataz A Shaldam; Amira El-Ganiny
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-04-23       Impact factor: 3.267

7.  The impact of diclofenac and ibuprofen on biofilm formation on the surface of polypropylene mesh.

Authors:  A Reśliński; S Dąbrowiecki; K Głowacka
Journal:  Hernia       Date:  2013-12-24       Impact factor: 4.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.